| Segment Reporting [Text Block] |
16. SEGMENT INFORMATION
Our business operations (being the development, manufacture and sale of products that improve the health and productivity of dairy and beef cattle) are described in Note 1, “Basis of Presentation and Significant Accounting Policies”. Our chief operating decision-maker (CODM), our President and CEO, regularly evaluates two operating segments: i) Scours and ii) Mastitis for purposes of deciding how to allocate resources and assess performance. Our CODM primarily evaluates performance based on product sales as well as net operating income (loss). No operating segments have been aggregated; therefore, our two operating segments are the Company's two reportable segments.
Scours segment - consists of the First Defense® product line. The core technology underlying the Scours segment is focused on polyclonal antibodies.
Mastitis segment - includes our CMT product line, consisting of reagents and equipment used for rapid cow-side testing to identify mastitic quarters by detecting elevated somatic cell counts. This segment also includes our Re-Tain® product in development for the treatment of subclinical mastitis based on the bacteriocin nisin. On December 23, 2025, we made the decision to cease our efforts to obtain FDA approval of Re-Tain® while continuing the stability testing and investigational studies to evaluate Re-Tain® performance.
Other - includes unallocated administrative and overhead expenses and other products.
| | | Three Months Ended June 30, 2026 | |
| | | Scours | | | Mastitis | | | Other | | | Total | |
| Product sales | | $ | 7,110,769 | | | $ | 75,344 | | | $ | — | | | $ | 7,186,113 | |
| Costs of goods sold | | | 4,686,934 | | | | 61,957 | | | | — | | | | 4,748,891 | |
| Gross profit | | | 2,423,835 | | | | 13,387 | | | | — | | | | 2,437,222 | |
| | | | | | | | | | | | | | | | | |
| Administrative expenses | | | — | | | | — | | | | 1,271,909 | | | | 1,271,909 | |
| Sales and marketing expenses | | | 1,110,727 | | | | — | | | | — | | | | 1,110,727 | |
| Product development expenses (income), net(1) | | | 143,438 | | | | (52,495 | ) | | | 28,709 | | | | 119,652 | |
| Other operating income(2) | | | — | | | | (2,000,000 | ) | | | — | | | | (2,000,000 | ) |
| Operating expenses (income) | | | 1,254,165 | | | | (2,052,495 | ) | | | 1,300,618 | | | | 502,288 | |
| | | | | | | | | | | | | | | | | |
| NET OPERATING INCOME (LOSS) | | $ | 1,169,670 | | | $ | 2,065,882 | | | $ | (1,300,618 | ) | | $ | 1,934,934 | |
(1) Includes a $0.1 million reversal of an annual regulatory sponsor fee that we were no longer required to obtain as a result of the decision to cease focus on Re-Tain®.
(2) Includes a $2.0 million settlement with a former contract manufacturer that compensated the Company for operating costs incurred in product development and contract performance related to the development of the Company’s Re-Tain® product. See Note 9 for additional discussion.
| | | Three Months Ended June 30, 2025 | |
| | | Scours | | | Mastitis | | | Other | | | Total | |
| Product sales | | $ | 6,398,517 | | | $ | 46,363 | | | $ | — | | | $ | 6,444,880 | |
| Costs of goods sold | | | 3,589,893 | | | | 37,063 | | | | — | | | | 3,626,956 | |
| Gross profit | | | 2,808,624 | | | | 9,300 | | | | — | | | | 2,817,924 | |
| | | | | | | | | | | | | | | | | |
| Administrative expenses | | | — | | | | — | | | | 720,418 | | | | 720,418 | |
| Sales and marketing expenses | | | 634,846 | | | | 61,240 | | | | — | | | | 696,086 | |
| Product development expenses | | | 93,011 | | | | 710,745 | | | | 28,102 | | | | 831,858 | |
| Operating expenses | | | 727,857 | | | | 771,985 | | | | 748,520 | | | | 2,248,362 | |
| | | | | | | | | | | | | | | | | |
| NET OPERATING INCOME (LOSS) | | $ | 2,080,767 | | | $ | (762,685 | ) | | $ | (748,520 | ) | | $ | 569,562 | |
| | | Scours | | | Mastitis | | | Other | | | Total | |
| Total Assets as of June 30, 2026(1) | | $ | 37,524,605 | | | $ | 122,726 | | | $ | 8,982,465 | | | $ | 46,629,796 | |
| Total Assets as of December 31, 2025(1) | | $ | 38,245,418 | | | $ | 134,138 | | | $ | 4,152,891 | | | $ | 42,532,447 | |
| Depreciation expense during the three months ended June 30, 2026 | | $ | 463,271 | | | $ | — | | | $ | 7,350 | | | $ | 470,621 | |
| Depreciation and amortization expense during the three months ended June 30, 2025 | | $ | 345,512 | | | $ | 314,175 | | | $ | 19,350 | | | $ | 679,037 | |
| Capital Expenditures during the three months ended June 30, 2026 | | $ | 727,931 | | | $ | — | | | $ | 6,008 | | | $ | 733,939 | |
| Capital Expenditures during the three months ended June 30, 2025 | | $ | 151,808 | | | $ | 1,079 | | | $ | 2,271 | | | $ | 155,158 | |
(1) Total assets for our Scours segment as of June 30, 2026 and December 31, 2025, includes property, plant and equipment, net of approximately $12,000,000 and $12,300,000, respectively, of idle assets, which primarily related to one of our manufacturing facilities that was previously utilized for Re-Tain® that we now plan to refit for use in producing First Defense® products.
| | | Six Months Ended June 30, 2026 | |
| | | Scours | | | Mastitis | | | Other | | | Total | |
| Product sales | | $ | 17,418,544 | | | $ | 124,864 | | | $ | — | | | $ | 17,543,408 | |
| Costs of goods sold | | | 10,354,685 | | | | 94,057 | | | | — | | | | 10,448,742 | |
| Gross profit | | | 7,063,859 | | | | 30,807 | | | | — | | | | 7,094,666 | |
| | | | | | | | | | | | | | | | | |
| Administrative expenses | | | — | | | | — | | | | 2,409,586 | | | | 2,409,586 | |
| Sales and marketing expenses | | | 2,336,687 | | | | 6,803 | | | | — | | | | 2,343,490 | |
| Product development expenses | | | 241,531 | | | | 115,904 | | | | 79,905 | | | | 437,340 | |
| Other operating income(1) | | | — | | | | (2,000,000 | ) | | | — | | | | (2,000,000 | ) |
| Operating expenses (income) | | | 2,578,218 | | | | (1,877,293 | ) | | | 2,489,491 | | | | 3,190,416 | |
| | | | | | | | | | | | | | | | | |
| NET OPERATING INCOME (LOSS) | | $ | 4,485,641 | | | $ | 1,908,100 | | | $ | (2,489,491 | ) | | $ | 3,904,250 | |
(1) Includes a $2.0 million settlement with a former contract manufacturer that compensated the Company for operating costs incurred in product development and contract performance related to the development of the Company’s Re-Tain® product. See Note 9 for additional discussion.
| | | Six Months Ended June 30, 2025 | |
| | | Scours | | | Mastitis | | | Other | | | Total | |
| Product sales | | $ | 14,427,003 | | | $ | 85,051 | | | $ | — | | | $ | 14,512,054 | |
| Costs of goods sold | | | 8,264,436 | | | | 75,722 | | | | — | | | | 8,340,158 | |
| Gross profit | | | 6,162,567 | | | | 9,329 | | | | — | | | | 6,171,896 | |
| | | | | | | | | | | | | | | | | |
| Administrative expenses | | | — | | | | — | | | | 1,343,260 | | | | 1,343,260 | |
| Sales and marketing expenses | | | 1,421,983 | | | | 130,761 | | | | — | | | | 1,552,744 | |
| Product development expenses | | | 186,496 | | | | 1,339,657 | | | | 62,552 | | | | 1,588,705 | |
| Operating expenses | | | 1,608,479 | | | | 1,470,418 | | | | 1,405,812 | | | | 4,484,709 | |
| | | | | | | | | | | | | | | | | |
| NET OPERATING INCOME (LOSS) | | $ | 4,554,088 | | | $ | (1,461,089 | ) | | $ | (1,405,812 | ) | | $ | 1,687,187 | |
| | | Scours | | | Mastitis | | | Other | | | Total | |
| Depreciation expense during the six months ended June 30, 2026 | | $ | 981,288 | | | $ | — | | | $ | 17,627 | | | $ | 998,915 | |
| Depreciation and amortization expense during the six months ended June 30, 2025 | | $ | 698,034 | | | $ | 628,834 | | | $ | 38,942 | | | $ | 1,365,810 | |
| Capital Expenditures during the six months ended June 30, 2026 | | $ | 886,663 | | | $ | 8,526 | | | $ | 15,980 | | | $ | 911,169 | |
| Capital Expenditures during the six months ended June 30, 2025 | | $ | 474,185 | | | $ | 7,752 | | | $ | 2,271 | | | $ | 484,208 | |
|